Review Article

Effect of Acupuncture on Cognitive Function of Insomnia Patients Compared with Drugs: A Protocol for Meta-analysis and Systematic Review

Shan Qin, Jing Jiang, Wen-Zhong Wu, Xiao-Qiu Wang, Han-Qing Xi, Qin-Qin Fang, Bin Xu, and Cheng-Yong Liu

1Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China
2Nanjing University of Chinese Medicine, China

Correspondence should be addressed to Cheng-Yong Liu; lcy8601@163.com

Received 22 July 2021; Accepted 30 August 2021; Published 13 September 2021

Academic Editor: Muh-Shi Lin

Copyright © 2021 Shan Qin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Insomnia, one of the common sleep disorders, is thought to have an adverse effect on cognitive function. At the same time, people with cognitive dysfunction are more prone to insomnia. At present, pharmacotherapy is the main treatment for insomnia, but there are some shortcomings such as poor long-term efficacy and potential dependence. There is some evidence that acupuncture has some advantages in alleviating insomnia and improving cognitive function. This study is aimed at investigating the effects of acupuncture and drugs on cognitive function in patients with insomnia and evaluating the efficacy and safety of these two interventions, providing strong evidence for clinical decision-making. The study will retrieve eight major databases: China National Knowledge Infrastructure, Wanfang Database, VIP Database for Chinese Technical Periodicals, SinoMed, PubMed, Web of Science, Embase, and Cochrane Library. Dissertations, conference papers, and ongoing experiments will also be retrieved for supplement. Literature screening and data extraction will be completed by two authors independently (JJ and X-QW). If there were any disagreements, they would be discussed or referred to a third person for adjudication (W-ZW). Authors will use Cochrane risk of bias tool to assess the included studies. The Review Manager Statistical (RevMan) software is used to conduct the statistical process of meta-analysis, and funnel plot is used to evaluate reporting biases. The Grading of Recommendations Assessment Development and Evaluation (GRADE) Profiler can be used to be aware of the quality of evidence.

1. Introduction

Insomnia is one of the most common sleep disorders [1], which is mainly manifested as dissatisfaction with sleep time and quality, accompanied by daytime dysfunction, even if there is a good sleep environment and sleep opportunities [2]. One-third of the population in the United States is affected by insomnia, among which the elderly are the most common [3]. Meanwhile, compared with men, women are more prone to insomnia [4]. With the development of society, work pressure, and interpersonal conflict, the incidence of insomnia is still on the rise [5]. In addition to the health risks, insomnia also carries a substantial economic burden, costing society up to 100 billion dollars a year [6]. Studies have shown that insomnia can lead to cognitive function decline in patients through accumulation of amyloid-beta protein and increase of inflammatory factors [7]. They have deficits in attention, memory, and executive function. Furthermore, there is an increased risk of safety accidents and complications such as dysphagia and diabetes [8–11]. Insomnia and dementia influence each other. Dementia patients are more likely than the general population to suffer from insomnia, showing reduced sleep efficiency, increased nocturnal arousal, and early wakefulness [12]. There is still no way to completely cure dementia, but there are ways to prevent it by treating insomnia. Treatments for insomnia
include psychotherapy, pharmacotherapy, and complementary and alternative therapies [13]. Among them, pharmacotherapy is the main way to treat insomnia at present [14]. The clinically commonly used sedative and hypnotic drugs are benzodiazepine receptor agonists, which are characterized by rapid absorption and quick action, but also have side effects such as “next day hangover” and potential dependence. At the same time, this drug can increase the risk of falling [15]. There are literatures which have been proved that acupuncture can effectively improve the quality of sleep and cognitive function [16–19]. It mainly improves the body’s self-regulation ability and self-recovery ability by acting on different acupuncture points, to achieve the therapeutic effect [20], and has the advantages of easy operation, no adverse reactions, and extensive indications [21]. There is currently no evidence to prove the difference in efficacy and safety between acupuncture and drugs in cognitive function of insomnia patients. This meta-analysis is the first quantitative study to compare acupuncture with drugs from this perspective and to analyze whether acupuncture is effective for any type of insomnia.

2. Materials and Methods

This protocol was registered at PROSPERO and written based on the guideline of Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocol (PRISMA-P) [22]. Details can be viewed in the Supplementary Table S1. PROSPERO registration number is CRD42021246046.

2.1. Criteria for Included Studies

2.1.1. Types of Studies. The study will take into account all relevant randomized controlled trials. Language and publication status is not restricted. Studies that do not specify the method of randomization, but only mention randomization, also can be included. Blindness and allocation concealment are not confined. Clinical controlled trials also meet the requirements of the study and can be included.

2.1.2. Types of Participants. Patients will be enrolled as long as they meet the diagnostic criteria for insomnia. There are no restrictions on gender, age, or nationality. Diagnostic criteria for insomnia are the following: International Statistical Classification of Diseases and Related Health Problems Version 10 (ICD-10) [23], Diagnostic and Statistical Manual of Mental Disorders Version 5 (DSM-5) [24], and International Classification of Sleep Disorder Version 3 (ICSD-3) [25]. Patients meeting other internationally recognized diagnostic criteria can also be included. If the diagnostic criteria are not clearly stated, the author will be contacted for further information [26]. Whether the patient is chronic insomnia or acute insomnia, simple insomnia or comorbid insomnia can be included.

2.1.3. Types of Intervention. The experimental group received acupuncture as intervention measure, and any form of acupuncture could be included, including electroacupuncture, filiform needle therapy, body acupuncture, and auricular acupuncture. In acupuncture acupoints, the time and frequency of treatment are not limited. The control group was treated by drugs with insomnia treatment indications, including benzodiazepine receptor agonists, melatonin receptor agonists, antihistamine H1 receptor drugs, and orexin receptor antagonists. Studies using sham acupuncture in control groups will not be included. Myocardial infarction, diabetes, Parkinson’s disease, and some other diseases are closely related to the decline of cognitive function [27–29]. The growth of age also affects people’s cognitive function, so elderly insomnia and comorbid insomnia are more prone to cognitive decline [30]. The study will allow the elderly with underlying diseases and comorbid insomnia patients to use basic drugs, but the control group and the experimental group must be used at the same time.

2.1.4. Types of Outcomes. The primary outcome indicators are the Montreal Cognitive Assessment Scale (MOCA) [31]. Secondary outcome indicators are Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index Scale (ISI) [32, 33], and the incidence of adverse events.

2.1.5. Exclusion Criteria. Research has critical data missing, and data cannot be obtained. Research that uses wrong randomized methods will be excluded (such as generating random sequences based on parity of birth dates); combination therapy should be excluded (for example, studies using acupuncture combined with cognitive behavioral therapy). Studies with a sample size less than 30 cases should be excluded.

2.2. Search Strategy

2.2.1. Electronic Searches. Eight databases will be retrieved: China National Knowledge Infrastructure, Wanfang Database, VIP Database for Chinese Technical Periodicals, SinoMed, PubMed, Web of Science, Embase, and Cochrane Library. Retrieval time is from database inception to March 1, 2021. MeSH (Medical Subject Headings) and free text (title and abstract) will be combined to search. These MESHs will be included: acupuncture, needling, acupuncture and moxibustion, acupuncture therapy, electroacupuncture, cognition, cognitive function, insomnia, sleep initiation and maintenance disorders, randomized controlled trial, trial, randomly, randomized, and rct. The Chinese database will use the Chinese translation of the above search terms. The retrieval process of Embase can be seen in the Supplementary Table S2.

2.2.2. Other Resources. Data from unpublished randomized controlled trials is available on the International Clinical Trials Registry, ClinicalTrials.gov, and Chinese Clinical Trial Registry. In addition, we will retrieve conference papers and dissertations to ensure that all randomized controlled trials that meet the criteria are retrieved to the maximum extent possible.

2.3. Data Collection and Analysis

2.3.1. Selection of Studies. Literature retrieval and screening will be conducted independently by two authors (H-QX and Q-QF). First of all, duplicate literatures will be excluded,
and a preliminary screening is conducted according to the title and abstract. Then, the literature that meets the standards will be screened by reading the full text. If there is a disagreement, the literature should be discussed or submitted to a third person (W-ZW) for evaluation. The EndNote software is used for literature management, and the reasons for exclusion should be recorded for excluded studies. Figure 1 shows the process of literature screening in this research.

2.3.2. Data Extraction. Two authors (JJ and X-QW) will independently produce a table to complete the data extraction work. The data extraction form includes the first author’s name, publication year, follow-up situation, sample size, intervention measures, outcome, allocation concealment, randomization, selective reporting, blind method, integrity of outcome data, and the characteristics of the subjects (age, gender, course of disease, and educational level). If the results of the data extraction diverge, they are discussed or referred to a third person (W-ZW) for adjudication.

2.3.3. Assessment of Risk of Bias in the Included Studies. This study will appraise the risk of bias according to the Cochrane Handbook bias risk assessment tool [34]. The risks of bias include selection bias, performance bias, detection bias, attrition bias, and reporting bias. The study will be classified into low risk of bias, high risk of bias, and unclear risk of bias. The two authors (H-QX and Q-QF) make the assessment, and if there is a disagreement, they discuss it or refer it to a third person (W-ZW).

2.3.4. Dealing with Missing Data. If the required data is lacking, the author of the article will be contacted for relevant information, and if the data is still not available, the study with missing data will be excluded.

2.3.5. Assessment of Heterogeneity. Heterogeneity is divided into clinical heterogeneity, methodological heterogeneity, and statistical heterogeneity. The clinical and methodological heterogeneity of the included studies is first assessed, and if the clinical heterogeneity is excessive, subgroup analysis will be performed based on clinical characteristics. Q statistic and $I^2$ statistic are used to complete the statistical heterogeneity assessment [35]. $P \geq 0.1$ and $I^2 \leq 25\%$ indicate low heterogeneity. $P < 0.1$ and $I^2 > 50\%$ indicate high heterogeneity. The source of heterogeneity should be carefully analyzed when $I^2 \geq 75$.

2.3.6. Assessment of Reporting Biases. If more than ten articles are included [36], the existence of reporting biases could be evaluated by the symmetry of the funnel plot.

2.3.7. Data Synthesis. The RevMan software will be used for data processing. The effect index of the continuity variables is SMD (standardized mean difference) with 95% CIs (95% confidence intervals), and the categorical variable is RR (relative risk) and with 95% CIs, both of which are analyzed by inverse square examination. Considering the potential heterogeneity among acupuncture studies, this study will put to use the random effects model. If the heterogeneity is too large to identify its possible source, only descriptive analysis will be performed [37].
2.3.8. Subgroup Analysis. If the included studies show obvious clinical heterogeneity, subgroup analysis will be conducted according to clinical characteristics. In this study, we will conduct subgroup analysis according to the gender and age of patients, the types of insomnia (such as simple insomnia/comorbid insomnia), acupuncture points, treatment duration and frequency, and acupuncture methods (such as electroacupuncture/filiform needle).

2.3.9. Sensitivity Analysis. This study will carry out sensitivity analysis by changing the effect indicators, statistical model, and deleting each included study one by one [38] to verify the stability of the study results. If different conclusions are reached, the results of the meta-analysis are carefully obtained by discussion between the two authors (SQ and W-ZW) or by evaluation by a third person (X-QW).

2.4. Evidence Quality Evaluation. Cochrane Handbook bias risk assessment tool and GRADE Profiler are used to evaluate the quality of evidence by evaluating the factors that reduce the quality of evidence (risk of bias, inconsistency, indirectness, imprecision, publication bias) and the factors that increase the quality of evidence (large effect value, confounding factors that reduce efficacy, dose-effect relation) [39]. Evidence quality can be divided into four grades: high, medium, low, and very low [40].

3. Discussion

The adverse effects of insomnia and cognitive decline have caused a considerable burden on individuals, families, and society, while the incidence of insomnia and dementia continues to rise. Correct measures for patients with insomnia help to avoid the continuous deterioration of the situation. Therefore, we urgently need a relevant meta-analysis to provide reliable evidence for medical decision-making. There have been meta-analyses on acupuncture for insomnia, but they only focused on the effects of acupuncture on sleep and did not study from the perspective of acupuncture improving cognitive function in patients with insomnia [41–45]. Different from some studies only included in patients with comorbid insomnia [41–43]; this study as long as patients meet the diagnostic criteria of insomnia, whether simple insomnia or comorbid insomnia, can be included. Although it may increase the heterogeneity of the study, we can analyze whether acupuncture is effective for any type of insomnia. This study mainly includes four aspects: determining the inclusion and exclusion criteria and retrieval strategies, screening out all eligible randomized controlled trials at home and abroad, data extraction, data analysis, and processing. The study will also strive to obtain reliable conclusions through heterogeneity test, subgroup analysis, and sensitivity analysis. In addition, this study collected the relevant data of adverse events and compared the safety of acupuncture and drugs while understanding their efficacy. However, this study also has limitations: by comparing acupuncture with drugs alone, we cannot prove which is the best choice among all treatment options for improving cognitive function in insomnia patients. If the study does not include enough high-quality randomized controlled trials, the results of meta-analysis may be affected. The electronic databases of countries such as Korea and Japan will not be searched, which may lead to the existence of selective bias [46]. Different acupuncture methods may increase the heterogeneity of the study, but we will conduct a subgroup analysis to address this issue. In addition to insomnia, cognitive decline is associated with a variety of causes, including age and neurodegenerative disease, and there is no way to determine whether the decline in cognitive function in the included patients is due to insomnia.

4. Conclusion

This is a protocol for systematic review and meta-analysis. It mainly describes the specific methods for conducting the research, aiming to make the evidence provided by meta-analysis more powerful and accurate.

Data Availability

The data analyzed and used to prepare this study are available from the corresponding author upon rational request.

Disclosure

What we write is a protocol for meta-analysis and systematic review. We will not violate the privacy and rights of any patient. The results will be published in peer-reviewed journals and at related conferences.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Co-first authors JJ and SQ made equal contributions. JJ, SQ, and W-ZW conceived this study. JJ, SQ, and H-QX drafted this manuscript. JJ and X-QW designed the literature retrieval strategy. X-QW, Q-QF, and W-ZW revised the manuscript. C-YL is the supervisor of this review. All authors approved the final version of the manuscript.

Acknowledgments

This work was supported by the Cadre Health Research Project of Jiangsu Provincial Health Commission (Grant Number BJ19024).

Supplementary Materials

Table S1: PRISMA-P Checklist. This protocol was written based on the guideline of Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocol (PRISMA-P), and Supplementary Table S1 shows the details of checklist. Table S2: search strategy: EMBASE. Details of EMBASE’s Search strategy can be seen in the Supplementary Table S2. (Supplementary Materials)
References

[1] D. Burman, “Sleep disorders: insomnia,” *FP Essentials*, vol. 460, pp. 22–28, 2017.

[2] P. Zhang and Z. Zhao, “Pay attention to the clinical practice of adult insomnia diagnosis and treatment guidelines,” *Zhonghua Shen Jing Ke Za Zhi*, vol. 51, no. 8, pp. 561–564, 2018.

[3] P. C. Bollu and H. Kaur, “Sleep medicine: insomnia and sleep,” *Missouri Medicine Clinics*, vol. 15, no. 2, pp. 319–340, 2020.

[4] M. A. Grandner, “Sleep, health, and society,” *Sleep Medicine Clinics*, vol. 15, no. 1, pp. 68–75, 2019.

[5] D. Riemann, C. Baglioni, C. Bassetti et al., “European guideline for the diagnosis and treatment of insomnia,” *Journal of Sleep Research*, vol. 26, no. 6, pp. 675–700, 2017.

[6] P. Taddei-Allen, “Economic burden and managed care considerations for the treatment of insomnia,” *The American Journal of Managed Care*, vol. 26, 4 Supplement, pp. S91–S96, 2020.

[7] S. Sadeghmousavi, M. Eskian, F. Rahmani, and N. Rezaei, “The effect of insomnia on development of Alzheimer’s disease,” *Journal of Neuroinflammation*, vol. 17, no. 1, p. 289, 2020.

[8] K. Jash, P. Gondaliya, P. Kirave, B. Kulkarni, A. Sunkaria, and K. Kalia, “Cognitive dysfunction: a growing link between diabetes and Alzheimer’s disease,” *Drug Development Research*, vol. 81, no. 2, pp. 144–164, 2020.

[9] M. C. Espinosa-Val, A. Martín-Martínez, M. Graupera et al., “Prevalence, risk factors, and complications of oropharyngeal dysphagia in older patients with dementia,” *Nutrients*, vol. 12, no. 3, p. 863, 2020.

[10] J. A. Brownlow, K. E. Miller, and P. R. Gehrman, “Insomnia and cognitive performance,” *Sleep Medicine Clinics*, vol. 15, no. 1, pp. 71–76, 2020.

[11] F. Yu and Z. Zhou, “Advances in research on sleep disorders and cognitive disorders,” *Chinese Journal of Stroke*, vol. 11, no. 11, pp. 966–972, 2016.

[12] L. Ferini-Strambi, A. Galbiati, F. Casoni, and M. Salson, “Therapy for insomnia and circadian rhythm disorder in Alzheimer disease,” *Current Treatment Options in Neurology*, vol. 22, no. 2, p. 4, 2020.

[13] A. Qaseem, D. Kansagara, M. A. Forciea, M. Cooke, T. D. Del, and for the Clinical Guidelines Committee of the American College of Physicians, “Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians,” *Annals of Internal Medicine*, vol. 165, no. 2, pp. 125–133, 2016.

[14] Z. Wang, W. Xie, J. Que et al., “Progress in the treatment of insomnia disorder by Zoazen Anshen capsule,” *Chinese Journal of Drug Dependence*, vol. 26, no. 6, pp. 407–410, 2017.

[15] Y. Jiang, Q. Xia, J. Wang et al., “Insomnia, benzodiazepine use, and falls among residents in long-term care facilities,” *International Journal of Environmental Research and Public Health*, vol. 16, no. 23, p. 4623, 2019.

[16] L. Zhang, Y. Tang, R. Hui et al., “The effects of active acupuncture and placebo acupuncture on insomnia patients: a randomized controlled trial,” *Psychology, Health & Medicine*, vol. 25, no. 10, pp. 1201–1215, 2020.

[17] Y. K. Wang, T. Li, L. J. Ha et al., “Effectiveness and cerebral responses of multi-points acupuncture for primary insomnia: a preliminary randomized clinical trial and fMRI study,” *BMC Complementary Medicine and Therapies*, vol. 20, no. 1, p. 254, 2020.

[18] Y. Jia, X. Zhang, J. Yu et al., “Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial,” *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, p. 556, 2017.

[19] J. W. Yang, G. X. Shi, S. Zhang et al., “Effectiveness of acupuncture for vascular cognitive impairment no dementia: a randomized controlled trial,” *Clinical Rehabilitation*, vol. 33, no. 4, pp. 642–652, 2019.

[20] H. Liu, “Mechanism of acupuncture and moxibustion treatment from the correlation between acupoints, meridians and viscera,” *Liaoning Journal of Traditional Chinese Medicine*, vol. 29, no. 3, p. 170, 2002.

[21] B. LIU, “Acupuncture should be the pioneer of complementary advantages and coordinated development of Chinese and western medicine,” *Zhongguo Zhen Jiu*, vol. 41, no. 1, p. 1, 2021.

[22] PRISMA-P Group, D. Moher, L. Shamseer et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement,” *Systematic Reviews*, vol. 4, no. 1, p. 1, 2015.

[23] World Health Organization, *International Classification of Diseases, ICD*, People’s Medical Publishing House, Beijing, 5th edition, 2013.

[24] American Academy of Sleep Medicine, *International classification of sleep disorders*, People’s Medical Publishing House, Beijing, 3rd edition, 2014.

[25] American Academy of Sleep Medicine, *International classification of sleep disorders*, People’s Medical Publishing House, Beijing, 3rd edition, 2014.

[26] D. Li, L. Zhu, and D. Liu, “Acupuncture for refractory gastroesophageal reflux disease: a systematic review and meta-analysis protocol,” *BMJ Open*, vol. 9, no. 8, article e030713, 2019.

[27] J. G. Goldman and E. Sieg, “Cognitive impairment and dementia in Parkinson disease,” *Clinics in Geriatric Medicine*, vol. 36, no. 2, pp. 365–377, 2020.

[28] C. L. Lin, W. C. Chien, C. H. Chung, and F. L. Wu, “Risk of type 2 diabetes in patients with insomnia: a population-based historical cohort study,” *Diabetes/Metabolism Research and Reviews*, vol. 34, no. 1, 2018.

[29] N. G. Altman, B. Izi-Balserak, E. Schopfer et al., “Sleep duration versus sleep insufficiency as predictors of cardiometabolic health outcomes,” *Sleep Medicine*, vol. 13, no. 10, pp. 1261–1270, 2012.

[30] J. M. Dzierzewski, N. Dautovich, and S. Ravyts, “Sleep and cognition in older adults,” *Sleep Medicine Clinics*, vol. 13, no. 1, pp. 93–106, 2018.

[31] Z. S. Nasreddine, N. A. Phillips, V. A. @dirian et al., “The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment,” *Journal of the American Geriatrics Society*, vol. 53, no. 4, pp. 695–699, 2005.

[32] D. J. Buyse, C. F. Reynolds III, T. H. Monk, S. R. Berman, and D. J. Kupfer, “The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research,” *Psychiatry Research*, vol. 28, no. 2, pp. 193–213, 1989.

[33] C. M. Morin, G. Belleville, L. Bélanger, and H. Ivers, “The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response,” *Sleep*, vol. 34, no. 5, pp. 601–608, 2011.

[34] C. Álvarez-Bueno, C. Pesce, I. Cavero-Redondo, M. Sánchez-López, M. J. Pardo-Guijarro, and V. Martinez-Vizcaíno,
“Association of physical activity with cognition, metacognition and academic performance in children and adolescents: a protocol for systematic review and meta-analysis,” *BMJ Open*, vol. 6, no. 6, article e011065, 2016.

[35] K. T. Houghton, A. Forrest, A. Awad et al., “Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis,” *BMJ Open*, vol. 7, no. 3, article e013433, 2017.

[36] R. Ren, J. Zhang, T. Zhang, Y. Peng, C. Tang, and Q. Zhang, “Auriculotherapy for sleep quality in people with primary insomnia: a protocol for a systematic review and meta-analysis,” *Medicine (Baltimore)*, vol. 98, no. 8, article e14621, 2019.

[37] J. Zhou, W. Peng, W. Li, and Z. Liu, “Acupuncture for patients with Alzheimer’s disease: a systematic review protocol,” *BMJ Open*, vol. 4, no. 8, article e005896, 2014.

[38] Z. Li, Y. Zhang, Y. Wang, X. Yan, and P. Xie, “Electroacupuncture for primary insomnia: protocol for a systematic review and meta-analysis,” *Medicine (Baltimore)*, vol. 97, no. 27, article e11063, 2018.

[39] H. Balshem, M. Helfand, H. J. Schünemann et al., “GRADE guidelines: 3. Rating the quality of evidence,” *Journal of Clinical Epidemiology*, vol. 64, no. 4, pp. 401–406, 2011.

[40] L. Shamseer, D. Moher, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation,” *BMJ*, vol. 349, p. g7647, 2015.

[41] T. Y. Choi, J. I. Kim, H. J. Lim, and M. S. Lee, “Acupuncture for managing cancer-related insomnia: a systematic review of randomized clinical trials,” *Integrative Cancer Therapies*, vol. 16, no. 2, pp. 135–146, 2017.

[42] F. Liu, J. You, Q. Li et al., “Acupuncture for Chronic Pain-Related Insomnia: A Systematic Review and Meta-Analysis,” *Evidence-based Complementary and Alternative Medicine*, vol. 2019, Article ID 5381028, 10 pages, 2019.

[43] B. Dong, Z. Chen, X. Yin et al., “The efficacy of acupuncture for treating depression-related insomnia compared with a control group: a systematic review and meta-analysis,” *BioMed Research International*, vol. 2017, Article ID 9614810, 11 pages, 2017.

[44] J. Zhang, Y. He, X. Huang, Y. Liu, and H. Yu, “The effects of acupuncture versus sham/placebo acupuncture for insomnia: a systematic review and meta-analysis of randomized controlled trials,” *Complementary Therapies in Clinical Practice*, vol. 41, p. 101253, 2020.

[45] F. Y. Zhao, Q. Q. Fu, G. A. Kennedy et al., “Can acupuncture improve objective sleep indices in patients with primary insomnia? A systematic review and meta-analysis,” *Sleep Medicine*, vol. 80, pp. 244–259, 2021.

[46] Z. Gao, C. M. Giovanardi, H. Li et al., “Acupuncture for migraine: a protocol for a meta-analysis and meta-regression of randomised controlled trials,” *BMJ Open*, vol. 8, no. 11, article e022998, 2019.